Login / Signup

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.

Zachary L WatsonTomomi M YamamotoAlexandra McMellenHyunmin KimConnor J HughesLindsay J WheelerMiriam D PostKian BehbakhtBenjamin G Bitler
Published in: Clinical epigenetics (2019)
This study demonstrates that disrupting EHMT1/2 sensitizes HGSOC cells to PARPi, and suggests a potential mechanism through DNA damage and cell cycle dysregulation. RNA-Seq identifies several unexplored pathways that may alter PARPi resistance. Further study of EHMT1/2 and regulated genes will facilitate development of novel therapeutic strategies to successfully treat HGSOC.
Keyphrases